Fulgent announced interim data from its Phase 2 study of FID-007 combined with cetuximab for recurrent/metastatic head and neck cancer, showing 60% objective response rate and favorable safety profile. The presentation at ASCO 2026 could validate the therapeutic potential of the company's oncology pipeline and support future clinical development.